NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AXSM

Axsome Therapeutics Inc

Jul 03 • 04:00PM ET

105.44

Dollar change +1.53
Percentage change 1.47	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD VRTX ALKS NBIX BHVN SAGE PRTA AVDL RARE

| Held by: VTI IWM VB VXF VBK IWO IBB SCHA VTWO IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.77	Insider Own	17.84%	Shs Outstand	49.22M	Perf Week	2.80%
Market Cap	5.19B	Forward P/E	65.34	EPS next Y	1.61	Insider Trans	-1.43%	Shs Float	40.45M	Perf Month	-4.24%
Enterprise Value	5.10B	PEG	-	EPS next Q	-1.05	Inst Own	75.73%	Short Float	9.93%	Perf Quarter	-3.93%
Income	-278.27M	P/S	12.01	EPS this Y	44.55%	Inst Trans	0.18%	Short Ratio	5.66	Perf Half Y	24.37%
Sales	432.16M	P/B	97.54	EPS next Y	148.59%	ROA	-48.72%	Short Interest	4.02M	Perf YTD	24.62%
Book/sh	1.08	P/C	17.25	EPS next 5Y	-	ROE	-282.16%	52W High	139.13 -24.21%	Perf Year	30.12%
Cash/sh	6.11	P/FCF	-	EPS past 3/5Y	-20.03% -24.44%	ROIC	-106.14%	52W Low	72.21 46.02%	Perf 3Y	177.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.61%	Volatility	2.86% 3.21%	Perf 5Y	22.90%
Dividend TTM	-	EV/Sales	11.81	EPS Y/Y TTM	9.65%	Oper. Margin	-55.36%	ATR (14)	3.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.96	Sales Y/Y TTM	72.16%	Profit Margin	-64.39%	RSI (14)	51.22	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	2.03	EPS Q/Q	15.71%	SMA20	0.42%	Beta	0.52	Target Price	176.94
Payout	-	Debt/Eq	3.97	Sales Q/Q	61.95%	SMA50	-1.17%	Rel Volume	0.35	Prev Close	103.91
Employees	683	LT Debt/Eq	3.93	Earnings	May 05 BMO	SMA200	2.34%	Avg Volume	710.22K	Price	105.44
IPO	Nov 19, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.71% 1.94%	Trades		Volume	245,787	Change	1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-25	Resumed	Morgan Stanley	Overweight	$190
Jun-03-25	Initiated	Oppenheimer	Outperform	$185
Apr-07-25	Initiated	Jefferies	Buy	$200
Feb-11-25	Initiated	Deutsche Bank	Buy	$176
Dec-31-24	Reiterated	Mizuho	Outperform	$124 → $122
Sep-03-24	Initiated	Wells Fargo	Overweight	$140
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy	$95 → $106
Jul-22-24	Initiated	Needham	Buy	$130
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$90 → $115
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$105 → $34
Jun-10-21	Initiated	Berenberg	Buy	$112
Jan-08-21	Initiated	Jefferies	Buy	$129

Show Previous Ratings

Today 07:48AM	Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment (Zacks)
03:23AM	Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle (Insider Monkey)
Jun-20-25 07:00AM	Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month (GlobeNewswire)
Jun-18-25 07:00AM	Axsome Therapeutics to Present Data Spanning the SYMBRAVO (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) (GlobeNewswire)
Jun-16-25 07:00AM	Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders (GlobeNewswire)
07:57PM	Loading…
Jun-11-25 07:57PM	Axsome's AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley (Insider Monkey)
07:00AM	Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 (GlobeNewswire)
Jun-10-25 07:00AM	Axsome Therapeutics Announces Availability of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jun-09-25 07:00AM	Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia (GlobeNewswire)
Jun-05-25 03:19AM	2 Soaring Stocks Wth More Upside Potential (Motley Fool)
Jun-04-25 11:30AM	Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? (Zacks)
May-29-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-28-25 07:00AM	Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
May-27-25 07:00AM	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd. (GlobeNewswire)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
07:30PM	Loading…
May-14-25 07:30PM	Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis (Motley Fool)
May-13-25 07:00AM	Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone (GlobeNewswire)
May-12-25 07:08AM	Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years (Motley Fool)
May-11-25 11:15AM	3 Monster Stocks in the Making (Motley Fool)
May-06-25 09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:02AM	Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:24AM	Q1 2025 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 11:44AM	Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 07:00AM	Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month (GlobeNewswire)
Apr-30-25 10:01AM	TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
Apr-22-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:52AM	Loading…
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -5.92%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 07:00AM	Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)
Apr-04-25 07:00AM	Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -8.37%
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 04:04PM	Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week (Investor's Business Daily)
01:23PM	Why Shares of Axsome Therapeutics Slumped Today (Motley Fool)
07:00AM	Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) (GlobeNewswire)
Mar-26-25 11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 06:47PM	Why Pharma and Biotech Stocks Got Thrashed on Tuesday (Motley Fool) -6.82%
12:53PM	IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint (GlobeNewswire)
Mar-21-25 11:36AM	Axsome: The Alzheimer's Agitation Program For AXS-05 (SeekingAlpha)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
11:30AM	Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 10:32AM	Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025? (Insider Monkey)
Mar-05-25 07:00AM	Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA (GlobeNewswire)
Mar-03-25 07:00AM	Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission (GlobeNewswire)
Mar-01-25 05:04PM	Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-26-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-25 01:34PM	Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs (Benzinga) -5.10%
07:00AM	Axsome Therapeutics Announces SYMBRAVO (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors (GlobeNewswire)
Feb-23-25 03:09PM	Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily) +6.70% -5.10%
Feb-19-25 02:48PM	Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
02:03AM	Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ... (GuruFocus.com)
01:06AM	Q4 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-18-25 11:15AM	Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-25 09:45AM	This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? (Motley Fool)
Feb-11-25 02:42PM	Why Axsome Therapeutics (AXSM) Is Advancing Today (Insider Monkey)
11:39AM	Why Axsome Therapeutics Stock Is Soaring Today (Motley Fool)
03:33AM	Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains? (Zacks)
Feb-10-25 02:45PM	Why Axsome Therapeutics Stock Is Skyrocketing Today (Motley Fool) +20.16%
12:33PM	Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' (Benzinga)
07:00AM	Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY (dextromethorphan HBr bupropion HCl) Patent Litigation (GlobeNewswire)
Jan-31-25 07:00AM	Axsome Therapeutics Hosts SYMBRAVO FDA Approval Virtual Investor Event with Expert Thought Leader (GlobeNewswire)
Jan-30-25 03:45PM	Axsome Therapeutics Announces FDA Approval of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jan-22-25 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 (GlobeNewswire) +6.33%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) +11.52% -5.23%
07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue (GlobeNewswire)
Dec-31-24 08:15AM	Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results (Benzinga)
Dec-30-24 05:07PM	Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation (GlobeNewswire)
Dec-12-24 11:30AM	Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? (Zacks)
Nov-27-24 01:23PM	Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says (Benzinga)
Nov-26-24 07:00AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy (GlobeNewswire)
Nov-13-24 03:27AM	Q3 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 03:15PM	Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript (Motley Fool) +9.35%
12:42PM	Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains (GuruFocus.com)
07:00AM	Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-24 07:00AM	Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 (GlobeNewswire)
Oct-19-24 07:30AM	3 Bargain Stocks to Buy in a Market That's Priced for Perfection (Motley Fool)
Oct-15-24 07:00AM	Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 (GlobeNewswire)
Sep-29-24 07:32AM	1 Under-the-Radar Biotech Stock to Buy and Hold (Motley Fool)
Sep-24-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 (GlobeNewswire)
Sep-04-24 07:00AM	Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine (GlobeNewswire) +6.59%
Aug-27-24 07:00AM	Axsome Therapeutics to Participate in Investor Conferences in September (GlobeNewswire)
Aug-21-24 07:00AM	Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc. (GlobeNewswire)
Aug-16-24 05:43AM	Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double (Insider Monkey)
Aug-05-24 01:45PM	Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript (Motley Fool)
12:15PM	Why Axsome Therapeutics Stock Is Sinking Today (Motley Fool)
11:30AM	Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:30AM	Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected (GlobeNewswire)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murdock Hunter R.	General Counsel	Jun 20 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Option Exercise	29.91	6,014	179,879	6,014	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Sale	102.47	7,500	768,525	0	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Sale	100.12	6,014	602,122	0	Jun 23 07:42 PM
Murdock Hunter R.	Officer	Jun 23 '25	Proposed Sale	100.12	6,014	602,101		Jun 23 04:01 PM
Murdock Hunter R.	Officer	Jun 20 '25	Proposed Sale	102.47	7,500	768,503		Jun 20 04:08 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Sale	102.42	7,500	768,150	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Sale	100.90	7,500	756,750	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Sale	100.26	7,500	751,950	0	Jun 18 09:16 PM
Murdock Hunter R.	Officer	Jun 18 '25	Proposed Sale	100.90	7,500	756,729		Jun 18 04:42 PM
Murdock Hunter R.	Officer	Jun 17 '25	Proposed Sale	100.26	7,500	751,975		Jun 17 04:01 PM
Murdock Hunter R.	Officer	Jun 16 '25	Proposed Sale	102.42	7,500	768,154		Jun 16 04:17 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Option Exercise	8.02	25,000	200,500	30,783	Jun 10 07:00 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Sale	110.44	25,000	2,761,000	5,783	Jun 10 07:00 PM
Jacobson Mark L.	Officer	Jun 09 '25	Proposed Sale	110.44	25,000	2,760,894		Jun 09 04:07 PM
Coleman Mark	Director	May 27 '25	Sale	105.47	3,750	395,512	50,387	May 29 07:00 PM
Coleman Mark	Director	May 28 '25	Sale	103.43	3,750	387,862	46,637	May 29 07:00 PM
Jacobson Mark L.	Chief Operating Officer	May 27 '25	Option Exercise	6.47	20,673	133,754	26,456	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 28 '25	Option Exercise	6.47	20,000	129,400	25,783	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 27 '25	Sale	104.66	20,673	2,163,636	5,783	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 28 '25	Sale	103.45	20,000	2,069,000	5,783	May 28 09:52 PM
Coleman Mark	Director	May 28 '25	Proposed Sale	103.43	3,750	387,858		May 28 05:04 PM
Jacobson Mark L.	Officer	May 28 '25	Proposed Sale	103.45	20,000	2,068,932		May 28 05:03 PM
Jacobson Mark L.	Officer	May 27 '25	Proposed Sale	0.00	20,673	1		May 27 04:46 PM
Coleman Mark	Director	May 27 '25	Proposed Sale	105.47	3,750	395,501		May 27 04:45 PM
Coleman Mark	Director	May 20 '25	Sale	107.49	3,000	322,473	54,137	May 20 09:46 PM
Coleman Mark	Director	May 20 '25	Proposed Sale	107.49	3,000	322,473		May 20 05:54 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Option Exercise	3.50	12,000	42,000	54,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Option Exercise	3.50	3,000	10,500	45,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Sale	129.86	12,000	1,558,320	42,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Sale	131.07	3,000	393,210	42,187	Feb 14 09:20 PM
Pizzie Nick	Officer	Feb 14 '25	Proposed Sale	131.07	3,000	393,202		Feb 14 04:09 PM
Pizzie Nick	Officer	Feb 13 '25	Proposed Sale	129.86	12,000	1,558,312		Feb 13 04:02 PM
Coleman Mark	Director	Jan 03 '25	Option Exercise	9.00	9,127	82,143	57,137	Jan 06 04:06 PM
Coleman Mark	Director	Nov 19 '24	Option Exercise	5.94	33,410	198,455	48,010	Nov 20 04:30 PM
Saad Mark E	Director	Sep 11 '24	Option Exercise	3.67	11,016	40,429	21,018	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Sale	91.31	11,016	1,005,871	10,002	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Proposed Sale	91.31	11,016	1,005,843		Sep 11 04:32 PM
Jacobson Mark L.	Chief Operating Officer	Aug 09 '24	Option Exercise	4.04	47,739	192,866	53,522	Aug 09 07:27 PM
Jacobson Mark L.	Chief Operating Officer	Aug 09 '24	Sale	84.26	47,739	4,022,488	5,783	Aug 09 07:27 PM
Jacobson Mark L.	Officer	Aug 09 '24	Proposed Sale	84.26	47,739	4,022,490		Aug 09 05:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXSM

Axsome Therapeutics Inc

Upgrade your FINVIZ experience